Clinical trial
R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of…
NCT00045123 · Myrexis Inc., Industry · Unknown status
Key facts
| NCT number | NCT00045123 |
|---|---|
| Title | R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence |
| Official title | Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and… |
| Lead sponsor | Myrexis Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Procedure |
| Interventions | tarenflurbil, adjuvant therapy |
| Start date | Feb 1, 2002 |
| First posted | Feb 6, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: